Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557196 | 0.83 | CYP1A2 (0.70) | CYP1A2KDM4EALDH1A1NPC1TP53 | |
| SCHEMBL130625 | 0.83 | CYP1A2 (0.70) | CYP1A2KDM4EALDH1A1NPC1TP53 | |
| Methane SCHEMBL28143132 | 0.81 | CYP1A2 (0.68) | CYP1A2KDM4EALDH1A1NPC1TP53 | |
| SCHEMBL1023212 | 0.78 | CYP1A2 (0.63) | CYP1A2KDM4EALDH1A1NPC1TP53 | |
| SCHEMBL9042255 | 0.76 | KDM4E (0.73) | CYP1A2KDM4EALDH1A1NPC1TP53 | |
| SCHEMBL3976004 | 0.76 | CYP1A2 (0.61) | CYP1A2KDM4EALDH1A1NPC1TP53 | |
| SCHEMBL9041896 | 0.76 | CYP1A2 (0.61) | CYP1A2KDM4EALDH1A1NPC1TP53 | |
| SCHEMBL25863815 | 0.76 | CYP1A2 (0.61) | CYP1A2KDM4EALDH1A1NPC1TP53 | |
| SCHEMBL16795434 | 0.74 | CYP1A2 (0.59) | CYP1A2PDPK1HPGDLMNAKMT2A | |
| SCHEMBL9042334 | 0.74 | CYP1A2 (0.59) | CYP1A2KDM4EALDH1A1NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234945-A1 | AZABICYCLYL-SUBSTITUTED HETEROCYCLES AS FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-27 | — | — | US | disclosed |
| US-8420651-B2 | Substituted 1-alkylcinnolin-4(1H)-one derivatives, preparation thereof and therapeutic application of same | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20120129864-A1 | SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME | SANOFI (FR) | 2012-05-24 | — | — | US | disclosed |
| US-6844342-B2 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| EP-1343499-A4 | HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040067997-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | YU KUO-LONG (US) | 2004-04-08 | — | — | US | disclosed |
| EP-1343499-A2 | HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002062290-A2 | HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129864-A1 | SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME | ALK, CBR1, CBR3 | CYP1A2 828/4885KDM4E 3133/4885ALDH1A1 718/4885 |
| US-20040067997-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 1326/4885KDM4E 294/4885ALDH1A1 2968/4885 |
| US-20230234945-A1 | AZABICYCLYL-SUBSTITUTED HETEROCYCLES AS FUNGICIDES | CYP1B1, DDT, CYP1A1 | CYP1A2 8/4885KDM4E 542/4885ALDH1A1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.